Phase-sensitive individualized pharmacotherapy for alcohol use disorder.

Area of Science:

• Neuroscience
• Psychiatry
• Digital Health

Background:

• Alcohol use disorder (AUD) is a widespread condition with significant patient suffering.
• Current pharmacotherapies for AUD have limited efficacy and poor patient compliance.
• Distinct neurobiological processes underlie different phases of AUD (e.g., seeking, consumption, withdrawal).

Purpose of the Study:

• To propose a novel, phase-sensitive treatment strategy for alcohol use disorder.
• To integrate available pharmacotherapies with advanced diagnostic technology for personalized AUD management.
• To leverage artificial intelligence (AI) for real-time monitoring and treatment guidance in AUD.

Main Methods:

• Development of a treatment strategy combining a pharmacological toolbox with an ecological momentary assessment (EMA) tool.
• Utilizing an AI-coupled EMA device for near real-time monitoring of individual AUD phases.
• Tailoring neuropharmacological interventions based on EMA-derived phase-specific data.

Main Results:

• The proposed strategy enables precise targeting of individual AUD phases.
• AI-coupled EMA acts as a diagnostic monitor, treatment guide, and success metric.
• This approach facilitates individualized, phase-sensitive neuropharmacological treatment for AUD.

Conclusions:

• This innovative approach integrating pharmacotherapy and AI-driven EMA may revolutionize AUD treatment.
• Personalized, phase-specific interventions hold promise for improving treatment efficacy and compliance.
• The strategy offers a potential paradigm shift in managing psychiatric disorders.